Exclusive Summary

• Backed by a planned 2027 US FDA filing, the stringent cGMP compliance dossiers can dramatically accelerate local registration and distribution approvals in EU and emerging markets.
• As a WHO Essential Medicine and strict first-line standard of care (NCCN guidelines) for CLL/AML, the full strength range (10/50/100mg) perfectly meets the uncompromisable clinical protocol for TLS dose-ramp-up.
• Strategically timed for the 2027-2030 global patent cliff, this first-wave generic leverages China's highly cost-effective API-to-FDF integrated supply chain to disrupt a $2 billion+ monolithic market.